FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MOLINA ARTURO MD 		2. Issuer Name and Ticker or Trading Symbol

Cougar Biotechnology, Inc. [ CGRB ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

10990 WILSHIRE BLVD., SUITE 1200 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/3/2009
(Street)

LOS ANGELES, CA 90024
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   $21.05   7/3/2009     D         160000      (1) 5/7/2017   Common Stock   160000   $21.95   0   D  
 
Stock Option (Right to Buy)   $34.09   7/3/2009     D         65000      (2) 8/1/2018   Common Stock   65000   $8.91   0   D  
 

Explanation of Responses:
( 1)  This option to purchase shares of the Issuer's common stock, which provided for vesting in four equal annual installments commencing on the first anniversary of the date of grant, became 100% vested and exercisable due to a change in control of the Issuer effected through the completion of a tender offer by Kite Merger Sub, Inc. ("Kite"), a wholly-owned subsidiary of Johnson & Johnson, effective as of July 2, 2009. As a result of the completion of the tender offer, this stock option was cancelled and the reporting person is entitled to a cash payment from the Issuer in the gross amount of $3,512,000.00, less applicable withholding, representing the difference between $43.00 (tender offer price) and the option exercise price for each share subject to this stock option.
( 2)  This option to purchase shares of the Issuer's common stock, which provided for vesting in four equal annual installments commencing on the first anniversary of the date of grant, became 100% vested and exercisable due to a change in control of the Issuer effected through the completion of a tender offer by Kite, effective as of July 2, 2009. As a result of the completion of the tender offer, this stock option was cancelled and the reporting person is entitled to a cash payment from the Issuer in the gross amount of $579,150.00, less applicable withholding, representing the difference between $43.00 (tender offer price) and the option exercise price for each share subject to this stock option.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
MOLINA ARTURO MD
10990 WILSHIRE BLVD., SUITE 1200
LOS ANGELES, CA 90024

Chief Medical Officer

Signatures
/s/ Arturo Molina, MD, MS 7/7/2009
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Cougar Biotechnology (MM) (NASDAQ:CGRB)
過去 株価チャート
から 11 2024 まで 12 2024 Cougar Biotechnology (MM)のチャートをもっと見るにはこちらをクリック
Cougar Biotechnology (MM) (NASDAQ:CGRB)
過去 株価チャート
から 12 2023 まで 12 2024 Cougar Biotechnology (MM)のチャートをもっと見るにはこちらをクリック